flumatinib
Small moleculeexperimental
Clinical trial activity
11 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
6
Earliest trial started Aug 1, 2011 (NCT01503502)
Timeline
Indications
Approved for
Studied for
- Drugs, Investigational · Phase 4
- Fusion Proteins, bcr-abl · Phase 4
- Imatinib Mesylate · Phase 4
- Leukemia · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 4
- Leukemia, Myeloid, Acute · Phase 4
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 4
- Leukemia, Myeloid, Chronic-Phase · Phase 4
- Philadelphia Chromosome · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 4
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
Mechanism of action
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1- Mol. weight
- 562.6 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545413 ↗
Also known as
- 4-(4-methylpiperazin-1-ylmethyl)-n-(6-methyl-5-(4-pyridin-3-ylpyrimidin-2-ylamino)pyridin-3-yl)-3-trifluoromethylbenzamide
- flumatinib
- flumatinib
- flumatinib
- flumatinib
- flumatinib
- hhgv678
- hh-gv678
- hh-gv-678
- hhgv-678
- hhgv-678
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06530810 | Phase 1 | Jul 31, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05433532 | Phase 2 | May 1, 2022 | Soochow University |
| NCT05367765 | Phase 4 | Apr 30, 2022 | Harbin Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05353205 | Phase 4 | Nov 23, 2021 | Harbin Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05071482 | Phase 4 | Sep 16, 2021 | Chinese Academy of Medical Sciences, Peking University |
| NCT04933526 | Phase 4 | Jul 1, 2021 | China Medical University |
| NCT04677439 | Phase 4 | Jan 1, 2021 | China Medical University, Hainan People's Hospital, Peking University, Sanya Central Hospital, Shantou University, Sun Yat-Sen University |
| NCT04375683 | Phase 4 | May 1, 2020 | Southeast University |
| NCT02204644 | Phase 3 | Jun 1, 2014 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT02511340 | Phase 2 | Jan 1, 2013 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Peking University |
| NCT01503502 | Phase 2 | Aug 1, 2011 | Chinese Academy of Medical Sciences, Hengrui Therapeutics, Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 5 | 5 | 4 | 2013 |
| Peking University | Academic/Hospital | 3 | 1 | 2 | 2013 |
| China Medical University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2011 |
| Harbin Medical University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Hainan People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2011 |
| Sanya Central Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Southeast University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
12 organizations
Page 1 / 1